



## **TO THE NATIONAL SECURITIES MARKET COMMISSION**

In compliance with the information duties set out in article 227 of the Revised Text of the Securities Market Act, approved by Royal Legislative Decree 4/2015, of October 23, Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, the "**Company**" or "**ROVI**"), informs the National Securities Market Commission of the following:

### **OTHER RELEVANT INFORMATION**

Yesterday, the President of the Board of Directors of Laboratorios Farmacéuticos Rovi, S.A., Mr. Juan López-Belmonte López passed away.

The First Vice President of the Board, Mr. Javier López-Belmonte Encina, will exercise the functions of the presidency until the appointment of a new President in accordance with the provided succession plans and corporate procedures.

The Company will always be grateful for the commendable work carried out by its President and it will honour his example.

Madrid, on 13 July 2021

Mr. Juan López-Belmonte Encina  
Chief Executive Officer  
Laboratorios Farmacéuticos ROVI, S.A.